瑞戈非尼致血小板减少1例  

A Case of Thrombocytopenia Caused by Regorafenib in Rectal Cancer

作　　者：魏瑞娜 李淑芳[1,2] WEI Rui-na;LI Shu-fang(Department of Pharmacy,Cancer Hospital of Henan University,Henan Zhengzhou 450000,China;The Third People’s Hospital of Zhengzhou,Henan Zhengzhou 450000,China)

机构地区：[1]河南大学附属肿瘤医院药学部,河南郑州450000 [2]郑州市第三人民医院药学部,河南郑州450000

出　　处：《中国药物评价》2022年第2期186-188,共3页Chinese Journal of Drug Evaluation

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20200721)。

摘　　要：分析1例晚期直肠癌患者使用瑞戈非尼后出现重度血小板减少的诊疗经过,通过文献分析,阐述瑞戈非尼致血小板减少的原因。在升血小板的治疗过程中,应根据患者的体重足量足疗程的使用促血小板生成素(rhTPO),最终患者血小板缓慢提升,病情趋于稳定。The process of diagnosis and treatment of a patient with severe thrombocytopenia in the course of treatment of advanced rectal cancer by regorafenib was analyzed.Through literature review and analysis,the main causes of thrombocytopenia induced by regorafenib were described.An enough dose and course of treatment of rh-TPO should be given on the basis of the patient′s weight in the treatment of thrombocytopenia.Eventually,the patient′s condition stabilized.

关 键 词：瑞戈非尼 直肠癌 血小板减少 促血小板生成素(rhTPO) 

分 类 号：R979.1[医药卫生—药品]